NovaBiotics
Aberdeen
About NovaBiotics
NovaBiotics Ltd is a clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. The Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®). NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $17.3M
- Last round: Series Unknown (May 2024)
- Website: novabiotics.co.uk
- Phone: +4401224711377
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/novabiotics-3821 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.